The epidermal growth factor receptor variant <scp>III</scp> (<scp>EGFR</scp>v<scp>III</scp>): where wild things are alteredHui Gan, Terrance G. Johns|FEBS Journal|2013Cited by 357
Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis ConsortiumKenneth Aldape, Nikolajs Zeps, Steven N. Kalkanis et al.|Neuro-Oncology|2018Cited by 202
A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumorsJean‐Charles Soria, Michael Millward, Hui Gan et al.|Annals of Oncology|2016Cited by 145
Association of Neurocognitive Deficits With Radiotherapy or Chemoradiotherapy for Patients With Head and Neck CancerAlona Zer, Lori J. Bernstein, Gregory R. Pond et al.|JAMA Otolaryngology–Head & Neck Surgery|2017Cited by 56
Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug ConjugateAndrew C. Phillips, Edward B. Reilly, Erwin R. Boghaert et al.|Molecular Cancer Therapeutics|2018Cited by 52